Open AccessOne-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
Author(s) -
Ali Salimi,
Natàlia Vilà,
Milad Modabber,
Michael A. Kapusta
Publication year - 2021
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/ijo.ijo_459_20
Subject(s) - aflibercept , medicine , bevacizumab , diabetic macular edema , visual acuity , ophthalmology , refractory (planetary science) , glycemic , retrospective cohort study , diabetic retinopathy , diabetes mellitus , chemotherapy , physics , astrobiology , insulin , endocrinology
A sub-population of patients with diabetic macular edema (DME) responds less effectively to off-label use of Bevacizumab. Approval of Aflibercept for DME has offered Bevacizumab nonresponders an alternative therapeutic option. Herein, we investigate the anatomical and functional changes associated with Aflibercept treatment in Bevacizumab nonresponders with chronic DME in a Canadian setting.